Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Misses Estimates By $1.23 EPS

Royalty Pharma (NASDAQ:RPRX) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.04 EPS for the quarter, missing the consensus estimate of $1.27 by ($1.23), FiscalAI reports. The firm had revenue of $674.14 million for the quarter, compared to the consensus estimate of $758.93 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%.

Here are the key takeaways from Royalty Pharma’s conference call:

• Royalty receipts grew 14% year over year in the second quarter, while portfolio receipts increased 6% to $773 million and portfolio cash flow reached $736 million, reflecting approximately 95% cash conversion.
• Royalty Pharma raised its 2026 guidance for the second consecutive quarter, now forecasting portfolio receipts of $3.4 billion to $3.5 billion and royalty-receipt growth of approximately 7% to 10%, despite expected headwinds from PROMACTA, TYSABRI biosimilars and the IRA.
• The company acquired a royalty on AstraZeneca’s cliramitug for up to $425 million, gaining a 3.75% worldwide sales royalty on a potential first-in-class treatment for transthyretin amyloid cardiomyopathy with projected peak royalties of approximately $110 million to $190 million.
• Royalty Pharma cited continued progress across its pipeline, including regulatory submissions and approvals, with 19 development-stage therapies and approximately $2 billion of potential peak royalties in the late-stage pipeline; key trial readouts are expected through 2027.
• The company ended June with $812 million in cash, $9.2 billion of investment-grade debt and leverage of 2.8 times adjusted EBITDA, while maintaining more than $4 billion of financial flexibility and returning approximately $367 million to shareholders in the first half.

Royalty Pharma Trading Up 0.5%

RPRX stock traded up $0.27 during trading on Wednesday, hitting $57.75. 3,536,445 shares of the company traded hands, compared to its average volume of 2,750,280. The company has a 50-day moving average of $56.39 and a 200-day moving average of $50.30. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. Royalty Pharma has a 1 year low of $34.08 and a 1 year high of $60.44. The firm has a market capitalization of $33.25 billion, a PE ratio of 39.29, a P/E/G ratio of 10.18 and a beta of 0.43.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $0.235 per share. The ex-dividend date is Friday, August 14th. This represents a $0.94 annualized dividend and a yield of 1.6%. Royalty Pharma’s dividend payout ratio is currently 63.95%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on RPRX shares. Citigroup upped their target price on Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. TD Cowen lifted their price target on shares of Royalty Pharma from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Bank of America restated a “buy” rating on shares of Royalty Pharma in a report on Wednesday. UBS Group upped their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. Finally, Morgan Stanley increased their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Royalty Pharma currently has an average rating of “Buy” and an average target price of $56.57.

Key Royalty Pharma News

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Royalty receipts and guidance increased. Portfolio Receipts rose 6% to $773 million, while Royalty Receipts grew 14%. Management raised its 2026 Portfolio Receipts outlook to $3.4 billion-$3.5 billion, signaling confidence in the underlying royalty portfolio. Royalty Pharma reports second quarter 2026 results
• Positive Sentiment: Cash generation remained strong. Net cash provided by operating activities reached $728 million, supporting Royalty Pharma’s ability to fund acquisitions, dividends and other shareholder returns. Adjusted earnings of $1.32 per share also exceeded the $1.27 consensus estimate and increased from $1.14 a year earlier. Royalty Pharma Q2 earnings report
• Neutral Sentiment: Reported results contain a measure-related discrepancy. MarketBeat cited GAAP EPS of $0.04 and revenue of $674.1 million, below consensus revenue of $758.9 million, while Zacks highlighted adjusted EPS of $1.32 and described revenue as beating estimates. Investors are likely emphasizing royalty receipts and adjusted earnings, but the difference between GAAP and adjusted results may add volatility. Royalty Pharma earnings report
• Negative Sentiment: Valuation and target-price risks remain. Royalty Pharma trades near the upper end of its 52-week range, while one brokerage consensus target of $56.57 is below the recent trading level. That could limit near-term upside unless the raised guidance translates into further analyst upgrades. Royalty Pharma target price coverage

Insider Buying and Selling

In other Royalty Pharma news, CFO Terrance P. Coyne sold 64,399 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $53.98, for a total value of $3,476,258.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $52.75, for a total transaction of $721,831.00. Following the sale, the executive vice president owned 18,197 shares of the company’s stock, valued at $959,891.75. This represents a 42.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 393,009 shares of company stock valued at $21,601,827 over the last quarter. Company insiders own 18.84% of the company’s stock.

Hedge Funds Weigh In On Royalty Pharma

Hedge funds and other institutional investors have recently modified their holdings of the company. CIBC Private Wealth Group LLC grew its stake in shares of Royalty Pharma by 66.4% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 446 shares during the last quarter. Larson Financial Group LLC increased its holdings in Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 306 shares during the period. Smartleaf Asset Management LLC raised its position in Royalty Pharma by 59.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,405 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 524 shares during the last quarter. Transamerica Financial Advisors LLC raised its position in Royalty Pharma by 10.7% during the 4th quarter. Transamerica Financial Advisors LLC now owns 5,158 shares of the biopharmaceutical company’s stock valued at $199,000 after purchasing an additional 498 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in Royalty Pharma in the 4th quarter worth approximately $205,000. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.